Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 14, 2009

 

 

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   0-27598   77-0210467

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

  (IRS Employer
Identification No.)

1212 Terra Bella Avenue

Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02. Results of Operations and Financial Condition.

On May 14, 2009, IRIDEX Corporation issued a press release discussing its financial results for its first fiscal quarter of 2009, which ended April 4, 2009. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

  

Description

99.1    Press Release dated May 14, 2009.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IRIDEX CORPORATION
By:   /s/ THEODORE A. BOUTACOFF
 

Theodore A. Boutacoff

President and Chief Executive Officer

Date: May 14, 2009


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Press Release dated May 14, 2009.
Press Release dated May 14, 2009

Exhibit 99.1

 

FOR IMMEDIATE RELEASE    Contact:    Jim Mackaness
      Chief Financial Officer
      650 940-4700

May 14, 2009

Mountain View, California

IRIDEX Reports First Quarter 2009 Financial Results

IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of 2009 ended April 4, 2009.

For the first quarter of 2009 the Company recorded a net profit of $0.2 million or $0.03 per diluted share compared to a net loss of $0.9 million or $0.10 per diluted share in the first quarter of 2008. Revenue for the first quarter of 2009 was $10.7 million, a 6.4% decrease from the $11.5 million reported for the first quarter of 2008.

Ophthalmology revenues were $7.5 million in the first quarter of 2009 consistent with $7.5 million for the comparable period in 2008. Ophthalmology recurring revenues, comprised of consumable products and service were $4.4 million for the first quarter of 2009, up 6.7% from $4.2 million for the first quarter 2008.

Total Aesthetics revenues were $3.2 million in the first quarter of 2009 compared with $3.9 million in the comparable period of 2008, a decrease of 18.9%.

Gross profit for the first quarter of 2009 was $5.0 million, compared with $4.8 million for the first quarter of 2008. Gross margins were 47.0% and 41.9% for the first quarter of 2009 and 2008, respectively, an improvement of 5.1% of revenues. Operating expenses for the first quarter 2009 were $4.7 million compared with $5.5 million for 2008, or 43.6% and 48.3% of revenues, respectively.

“Returning to profitability given the current distressed economic environment represents a major accomplishment for the company,” stated Mr. Theodore A. Boutacoff, President and CEO. “This is the first quarter that we have been profitable on an operating income level since the fourth quarter of 2005. Keys to achieving profitability during the quarter were improvement in our gross margins to 47% of revenues and managing our operating expenses exceptionally well.

“Our profitable performance during the first quarter reflects steady progress towards successfully implementing our strategic objectives,” Mr. Boutacoff continued, “which are: continuing to manage the Company to be cash flow positive while driving profitability; putting the majority of our focus on our Ophthalmology business and looking to invest in growth opportunities for Ophthalmology.

“During the first quarter our financial strength continued to improve with $0.9 million in cash generated from operations which allowed us to increase our cash balance and at the same time start reducing our bank debt; as a result we now have cash in excess of our debt,” continued Mr. Boutacoff. “We believe our strategy of continuing to focus on our Ophthalmology business is bearing fruit. Our Ophthalmology recurring revenues


have grown quarter over comparable quarter even in these tough times. Furthermore, we announced that the first shipment of the IQ 577, our high-power, true yellow (577 nm wavelength) laser system for use by ophthalmologists was shipped in April for commercial sale, and we see the addition of the IQ 577 to our Ophthalmology product line as reinforcement of the IRIDEX brand for high quality technically advanced Ophthalmology products.”

Cash and cash equivalents were $5.7 million as of April 4, 2009, up from $5.3 million in January 3, 2009, while bank debt was $5.5 million as of April 4, 2009, down from $6.0 million as of January 3, 2009.

Conference Call

IRIDEX management will conduct a conference call later today, Thursday, May 14, 2009 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (877) 941-9205 (U.S.) or (480) 629-9041 (International) and quoting Conference ID 4075884, or by visiting the Company’s website at www.iridex.com. A telephone replay will be available beginning on Thursday, May 14, 2009 through Thursday, May 21, 2009 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4075884. In addition, later today an archived version of the webcast will be available on the Company’s website at www.iridex.com.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, consumable laser probes and delivery devices used to treat eye diseases in ophthalmology and skin conditions in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company’s website at http://www.iridex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company’s financial stability, growth strategy and prospects. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2009 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

 

     Three Months Ended  
     April 4,
2009
    March 29,
2008
 

Revenues

   $ 10,736     $ 11,474  

Cost of revenues

     5,688       6,669  
                

Gross profit

     5,048       4,805  
                

Operating expenses:

    

Research and development

     841       1,025  

Sales and marketing

     2,351       2,613  

General and administrative

     1,493       1,905  
                

Total operating expenses

     4,685       5,543  
                

Income (loss) from operations

     363       (738 )

Interest and other expense, net

     (139 )     (154 )
                

Income (loss) before income taxes

     224       (892 )

Provision for income taxes

     —         —    
                

Net income (loss)

   $ 224     $ (892 )
                

Net income (loss) per share - basic and diluted

   $ 0.03     $ (0.10 )
                

Shares used in computing net income (loss) per share - basic and diluted

     8,825       8,824  
                


IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

     April 4,
2009
    January 3,
2009
 
     (unaudited)        
Assets     

Current Assets:

    

Cash and cash equivalents

   $ 5,662     $ 5,307  

Accounts receivable, net

     7,809       8,199  

Inventories, net

     11,164       11,644  

Prepaids and other current assets

     516       540  
                

Total current assets

     25,151       25,690  

Property and equipment, net

     710       832  

Other intangible assets, net

     1,394       1,474  

Other long term assets

     310       229  
                

Total assets

     27,565       28,225  
                
Liabilities and Stockholders’ Equity     

Current Liabilities:

    

Accounts payable

   $ 1,951     $ 2,415  

Bank line of credit

     5,477       6,000  

Accrued compensation

     1,823       1,729  

Accrued expenses

     2,151       2,249  

Accrued warranty

     1,294       1,345  

Deferred revenue

     2,733       2,741  

Bank term loan

     —         —    
                

Total current liabilities

     15,429       16,479  
                

Stockholders’ Equity:

    

Convertible preferred stock

     5       5  

Common Stock

     89       89  

Additional paid-in capital

     39,244       39,105  

Accumulated other comprehensive loss

     (165 )     (192 )

Treasury stock, at cost

     (430 )     (430 )

Accumulated deficit

     (26,607 )     (26,831 )
                

Total stockholders’ equity

     12,136       11,746  
                

Total liabilities and stockholders’ equity

   $ 27,565     $ 28,225